B Szekely1, V Bossuyt2, X Li3, V B Wali3, G A Patwardhan3, C Frederick3, A Silber3, T Park4, M Harigopal2, V Pelekanou2, M Zhang2, Q Yan3, D L Rimm2, G Bianchini5, C Hatzis3, L Pusztai6. 1. Breast Medical Oncology, Yale Cancer Center, Yale University, New Haven, USA; Department of Oncological Internal Medicine and Clinical Pharmacology "B", National Institute of Oncology, Budapest, Hungary. 2. Departments of Pathology, Yale School of Medicine, New Haven, USA. 3. Breast Medical Oncology, Yale Cancer Center, Yale University, New Haven, USA. 4. Departments of Surgery, Yale School of Medicine, New Haven, USA. 5. Department of Breast Medical Oncology, Hospital San Raphael, Milan, Italy. 6. Breast Medical Oncology, Yale Cancer Center, Yale University, New Haven, USA. Electronic address: lajos.pusztai@yale.edu.
Abstract
Background: Little is known about how the immune microenvironment of breast cancer evolves during disease progression. Patients and methods: We compared tumor infiltrating lymphocyte (TIL) count, programmed death-ligand 1 (PD-L1) protein expression by immunohistochemistry and mRNA levels of 730 immune-related genes using Nanostring technology in primary and metastatic cancer samples. Results: TIL counts and PD-L1 positivity were significantly lower in metastases. Immune cell metagenes corresponding to CD8, T-helper, T-reg, Cytotoxic T, Dendritic and Mastoid cells, and expression of 13 of 29 immuno-oncology therapeutic targets in clinical development including PD1, PD-L1, and CTLA4 were significantly lower in metastases. There was also coordinated down regulation of chemoattractant ligand/receptor pairs (CCL19/CCR7, CXCL9/CXCR3, IL15/IL15R), interferon regulated genes (STAT1, IRF-1,-4,-7, IFI-27,-35), granzyme/granulysin, MHC class I and immune proteasome (PSMB-8,-9,-10) expression in metastases. Immunotherapy response predictive signatures were also lower. The expression of macrophage markers (CD163, CCL2/CCR2, CSF1/CSFR1, CXCR4/CXCL12), protumorigenic toll-like receptor pathway genes (CD14/TLR-1,-2,-4,-5,-6/MyD88), HLA-E, ecto-nuclease CD73/NT5E and inhibitory complement receptors (CD-59,-55,-46) remained high in metastases and represent potential therapeutic targets. Conclusions: Metastatic breast cancers are immunologically more inert than the corresponding primary tumors but some immune-oncology targets and macrophage and angiogenesis signatures show preserved expression and suggest therapeutic combinations for clinical testing.
Background: Little is known about how the immune microenvironment of breast cancer evolves during disease progression. Patients and methods: We compared tumor infiltrating lymphocyte (TIL) count, programmed death-ligand 1 (PD-L1) protein expression by immunohistochemistry and mRNA levels of 730 immune-related genes using Nanostring technology in primary and metastatic cancer samples. Results: TIL counts and PD-L1 positivity were significantly lower in metastases. Immune cell metagenes corresponding to CD8, T-helper, T-reg, Cytotoxic T, Dendritic and Mastoid cells, and expression of 13 of 29 immuno-oncology therapeutic targets in clinical development including PD1, PD-L1, and CTLA4 were significantly lower in metastases. There was also coordinated down regulation of chemoattractant ligand/receptor pairs (CCL19/CCR7, CXCL9/CXCR3, IL15/IL15R), interferon regulated genes (STAT1, IRF-1,-4,-7, IFI-27,-35), granzyme/granulysin, MHC class I and immune proteasome (PSMB-8,-9,-10) expression in metastases. Immunotherapy response predictive signatures were also lower. The expression of macrophage markers (CD163, CCL2/CCR2, CSF1/CSFR1, CXCR4/CXCL12), protumorigenic toll-like receptor pathway genes (CD14/TLR-1,-2,-4,-5,-6/MyD88), HLA-E, ecto-nuclease CD73/NT5E and inhibitory complement receptors (CD-59,-55,-46) remained high in metastases and represent potential therapeutic targets. Conclusions: Metastatic breast cancers are immunologically more inert than the corresponding primary tumors but some immune-oncology targets and macrophage and angiogenesis signatures show preserved expression and suggest therapeutic combinations for clinical testing.
Authors: Sara M Tolaney; Romualdo Barroso-Sousa; Tanya Keenan; Tianyu Li; Lorenzo Trippa; Ines Vaz-Luis; Gerburg Wulf; Laura Spring; Natalie Faye Sinclair; Chelsea Andrews; Jessica Pittenger; Edward T Richardson; Deborah Dillon; Nancy U Lin; Beth Overmoyer; Ann H Partridge; Eliezer Van Allen; Elizabeth A Mittendorf; Eric P Winer; Ian E Krop Journal: JAMA Oncol Date: 2020-10-01 Impact factor: 31.777
Authors: Susana Garcia-Recio; Aatish Thennavan; Michael P East; Joel S Parker; Juan M Cejalvo; Joseph P Garay; Daniel P Hollern; Xiaping He; Kevin R Mott; Patricia Galván; Cheng Fan; Sara R Selitsky; Alisha R Coffey; David Marron; Fara Brasó-Maristany; Octavio Burgués; Joan Albanell; Federico Rojo; Ana Lluch; Eduardo Martinez de Dueñas; Jeffery M Rosen; Gary L Johnson; Lisa A Carey; Aleix Prat; Charles M Perou Journal: J Clin Invest Date: 2020-09-01 Impact factor: 14.808
Authors: Adrienne G Waks; Daniel G Stover; Elizabeth A Mittendorf; Sara M Tolaney; Jennifer L Guerriero; Deborah Dillon; William T Barry; Evisa Gjini; Christina Hartl; Wesley Lo; Jennifer Savoie; Jane Brock; Robert Wesolowski; Zaibo Li; Adrienne Damicis; Anne V Philips; Yun Wu; Fei Yang; Amy Sullivan; Patrick Danaher; Heather Ann Brauer; Wafa Osmani; Mikel Lipschitz; Katherine A Hoadley; Michael Goldberg; Charles M Perou; Scott Rodig; Eric P Winer; Ian E Krop Journal: Clin Cancer Res Date: 2019-05-06 Impact factor: 12.531
Authors: Leisha A Emens; Sylvia Adams; Ashley Cimino-Mathews; Mary L Disis; Margaret E Gatti-Mays; Alice Y Ho; Kevin Kalinsky; Heather L McArthur; Elizabeth A Mittendorf; Rita Nanda; David B Page; Hope S Rugo; Krista M Rubin; Hatem Soliman; Patricia A Spears; Sara M Tolaney; Jennifer K Litton Journal: J Immunother Cancer Date: 2021-08 Impact factor: 13.751
Authors: Deborah Blythe Doroshow; Sheena Bhalla; Mary Beth Beasley; Lynette M Sholl; Keith M Kerr; Sacha Gnjatic; Ignacio I Wistuba; David L Rimm; Ming Sound Tsao; Fred R Hirsch Journal: Nat Rev Clin Oncol Date: 2021-02-12 Impact factor: 66.675